dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi]
dextroamphetamine sulfate
RxCUI: 1426251
What the CMS Formulary Data Shows for dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi]
Per the CMS 2026 Part D formulary file, dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] (RxNorm concept RXCUI 1426251, generic name dextroamphetamine sulfate) appears on 4 distinct formulary files spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 2, with a cross-plan average of Tier 1.5.
Real-world access to dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 9,950 Part D beneficiaries filled dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] in 2023, with total plan-and-beneficiary spending of $5,176,356 and an average per-beneficiary annual cost of $520.24. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 2
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
2023 Medicare Spending
- Beneficiaries
- 9,950
- Total spending
- $5,176,356
- Avg per beneficiary
- $520.24
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Mass General Brigham SCO (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham Advantage (PPO) | Mass General Brigham Health Plan, Inc. | T2 | No | $0 | MA |
| Mass General Brigham Advantage Secure (HMO-POS) | Mass General Brigham Health Plan, Inc. | T2 | No | $62.00 | MA |
| Mass General Brigham Advantage Premier (PPO) | Mass General Brigham Health Plan, Inc. | T2 | No | $79.70 | MA |
| Mass General Brigham Advantage Signature (PPO) | Mass General Brigham Health Plan, Inc. | T2 | No | $147.20 | MA |
Frequently Asked Questions
Is dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] covered by Medicare Part D?
Yes, dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] on Medicare Part D plans?
dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] averages Tier 1.5 across Part D plans, ranging from Tier 1 to Tier 2.
Does dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] require prior authorization?
0% of Part D formularies require prior authorization for dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi]. Step therapy: 0%. Quantity limits: 100%.
How much does Medicare spend on dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi]?
In 2023, total Medicare Part D spending on dextroamphetamine sulfate 2.5 MG Oral Tablet [Zenzedi] was $5,176,356, covering 9,950 beneficiaries. The average spend per beneficiary was $520.24.
Read our methodology - how this data is sourced, computed, and verified.